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Abstract
Despite the favorable effects reported with opioid switching performed in a specialized unit in the short term,
data on long-term basis are poor, particularly after discharging patients home or in other settings.
Research design and methods:
The aim of this prospective study was to evaluate the long-term outcome of patients who were switched in
an acute palliative care unit at a high volume of opioid switching. A consecutive sample of patients who
underwent opioid substitution during admission in an acute palliative care unit were assessed for a period of
1 year. Patients were followed-up for 4 weeks after being discharged. Patients were contacted by phone or
visited at the outpatient clinic 4 weeks after discharge. Epidemiological data, pain mechanisms, reason for
switching, number of opioid substitutions during admission, drugs, doses and routes of administration,
opioid treatment at discharge, pain intensity, distress score (DS) calculated as a sum of symptom intensity,
were recorded after 2 weeks (T2) and 4 weeks (T4).
A total of 76 patients underwent an opioid substitution in the period taken into consideration. Seventeen
patients were excluded as they died in the unit or underwent an alternative procedure after unsuccessful
opioid trials. A total of 50 patients were consecutively assessed and discharged after performing an opioid
switching. The mean age was 63 (11) years, and 29 were males. Of the 31 patients, 29 patients were
switched during admission once and twice or more, respectively. In all, 32 patients had a complete
assessment at T2 and T4. In 13 patients the switching was definitive, as they maintained the same drug
and the same dose. Other patients required the same changes to opioid therapy, including doses and drugs.
Only a minority of patients worsened their pain and/or symptom control in the subsequent assessments after
discharge.
Conclusions:
Opioid switching performed in acute pain relief and palliative care is an effective method of improving the
balance between analgesia and adverse effects, even for prolonged periods of time, following discharge to
another setting of care. However, for different reasons, some of patients may lose this benefit. Additional
studies using different models of care should be performed in order to gather further information about the
long-term outcome of opioid switching.
Introduction
The majority of patients with cancer pain can be adequately treated with oral
analgesics usually provided ‘around the clock’ with rescue doses for breakthrough
pain. Nevertheless, some patients develop uncontrolled adverse effects, includ-
ing generalized myoclonus, delirium, nausea and vomiting, or encounter severe
sedation before achieving adequate analgesia during dose titration. In other
patients dose escalation of one opioid may provide poor clinical benefit. The
substitution of another opioid for a previous one in order to obtain a more
favorable clinical response has largely been reported as opioid switching1.
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Sequential therapeutic trials with different opioids have
been claimed to improve the balance between analgesia
and adverse effects in difficult pain conditions. Opioid
switching is going to be a popular approach, although
data on the use of this practice are poor and difficult to
determine and controlled studies are a difficult to under-
take in this setting2. According to available data, opioid
switching will result in clinical improvement in 50–80% of
patients with cancer pain who present with a poor response
to one opioid1. Despite the favorable effects reported with
opioid switching performed in a specialized unit in the
short term3, data on longer-term results are poor, particu-
larly after discharging patients home or other settings. The
aim of this prospective study was to evaluate the long-term
outcome of patients who were switched in an acute palli-
ative care unit at a high volume of opioid switching.
Patients and methods
A consecutive sample of patients who underwent opioid
substitution successfully during admission in an acute pal-
liative care unit were assessed for a period of 1 year.
Informed consent and institutional approval were
obtained. Opioid switching was performed according to
local protocols described elsewhere3.
Patients were followed up for 4 weeks after being dis-
charged. Patients who died in the unit after switching or
patients who underwent alternative procedures because of
an unsuccessful switching, were excluded. After discharge,
patients were contacted by phone or visited at the outpa-
tient clinic at 1-week intervals for 4 weeks to gather infor-
mation about the clinical situation and to offer eventual
changes in the treatment according to the clinical
condition.
The following data were recorded: epidemiological
data, pain mechanisms, reason for switching, number of
opioid substitutions during admission, drugs, doses and
routes of administration, opioid treatment at discharge,
pain intensity (numerical scale 0–10), opioid-related
symptoms, including nausea and vomiting, drowsiness,
confusion, and constipation by using a scale from 0 to 3
(absent, slight, moderate, severe). A distress score (DS)
was calculated as a sum of symptom intensity. Although
never validated, this score has been previously used in dif-
ferent studies for determining the ‘weight’ of adverse
effects. The aim of using a sum of intensities is justified
by the high variability of symptom intensity in individual
patients. This score is able to determine a general improve-
ment of symptoms. The evaluation of the changes in inten-
sity of a single symptom, different for each patient, makes a
global evaluation and statistics for a group of patients prac-
tically impossible. Moreover, it is not unusual to switch a
patient for more than one symptom. Changes in DS have
been already used to assess outcome of switching. On the
other hand an important decrease in the principal symp-
tom which required the switching is another parameter to
take into consideration. Thus, these parameters have been
used to assess opioid switching3. Symptoms were assessed
by the patient, whenever possible. However, patients who
had severe cognitive failure, a proxy evaluation was taken
into account. Daily doses of opioids, pain and DS were
recorded at discharge (T0) and after 2 weeks (T2) and 4
weeks (T4).
Descriptive statistics were used to summarize the data.
Data were collected and analyzed by SPSS Software 14.0
version (SPSS, Inc., Chicago, IL, USA). Statistical anal-
ysis of quantitative and qualitative data, included descrip-
tive statistics, was performed for all the items. Frequency
analysis was performed with Pearson’s chi-square test. The
paired Wilcoxon signed-rank test was used to compare
pain intensity scores and symptom intensity scores over
weekly periods. All p-values were two-sided and p-values
less than 0.05 were considered to indicate statistical
significance.
Results
A total of 67 patients underwent an opioid substitution in
the period taken into consideration. In all, 17patients were
excluded as they died in the unit or underwent alternative
procedure after unsuccessful opioid trials. A total of 50
patients were consecutively assessed and discharged after
opioid switching had been performed. In all, 14 patients
were switched for adverse effects, 17 patients for uncon-
trolled pain,17 for both, and two for convenience.
The mean age was 63 (11) years, and 29 were males.
Primary diagnosis was in a rank order: lung (16), genito-
urinary (13), gastrointestinal (7), breast (6), other (8). The
median Karnofsky status of patients who were discharged
after a successful opioid switching was 40 (range 30–70).
A total of 31 and 29 patients were switched during
admission once and twice or more, respectively. The
majority of patients (29) were finally switched to metha-
done (two of them to intravenous methadone).
Thirteen patients were not evaluated because they died
before T2, were receiving low doses of opioids (less than
60mg of oral morphine equivalents), discontinued opioid
treatment, or were lost in follow-up. Five patients died or
were lost in follow-up between T2 and T4, and could not
be assessed at T4. One of these patients, who was receiving
130mg/day of intravenous methadone, was transferred to a
hospice, where he was switched to oral oxycodone because
of unavailability of intravenous methadone. One patient
was discharged on transdermal fentanyl 0.6mg/day. The
same dose was maintained successfully at T2. The patient
was then lost in follow-up. One patient was discharged on
hydromorphone 16mg/day, maintaining the same dose
successfully at T2 and died before T4. One patient was
Current Medical Research & Opinion Volume 27, Number 12 December 2011
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discharged on oral methadone 60mg/day. At T2 he
was receiving methadone 45mg and hydromorphone
16mg/day and died before T4. Finally, one patient was
discharged on methadone 12mg/day, maintaining the
same dose at T2, and died before T4.
A total of 32 patients had a complete assessment at T2
and T4. Data regarding this group of patients are presented
in Table 1. In 13 patients the switching was definitive, as
they maintained the same drug and the same dose. Other
patients required the same changes to opioid therapy,
including doses and drugs. Pain intensity, DS, and
number of patients whose pain was not considered effec-
tively controlled, at T0, T2, and T4, are presented in
Table 2. A minority of patients had their pain uncon-
trolled in the subsequent assessments after discharge.
However, a significant change in pain intensity and DS
was observed at T2 and T4.
Discussion
Although evidence for the efficacy of opioid switching is
lacking, this practice may be useful in cancer patients with
an unacceptable balance between analgesia and adverse
effects2. Opioid switching may occur more frequently in
an acute palliative care unit, possibly because of the more
selective population with relevant clinical problems, par-
ticularly uncontrolled pain, or high doses of opioids.
Moreover, since it is well-recognized that drug tolerance
represents the most frequent cause of opioid escalation and
sometime of opioid hyperalgesia, opioid switching may be
considered as an efficacious way of preventing these
phenomena during opioid therapy of chronic cancer
pain. It has been reported that opioid switching rate may
be as high as 34% of patients admitted for pain control3.
While opioid switching may improve the balance between
analgesia and adverse effects in most cases and patients can
be discharged in a relative state of stabilization, the dura-
tion of such a condition may be short-lived or unstable,
particularly when patients are then followed-up in other
settings. This study showed that opioid switching main-
tains its efficacy after patients’ discharge. Most patients
reported an adequate pain control and a large proportion
of them remained stable for 4 weeks, maintaining the same
drug and the some dose. However, about one-half of
patients may require further assessment, as they may
need to change the dose, or in a minority of cases to
switch to another drug. Moreover a trend in the increase
of pain intensity and DS was observed. Regrettably, some
patients lost their pain control, although the reasons for
this – for example inadequate treatment or loss of respon-
siveness – are unclear. Of interest, the decision to change
opioid therapy has multiple influences, based on the care
setting following patient discharge from the acute pallia-
tive care unit, including hospice care, GP care, home pal-
liative care program, or poor family compliance,
independently of phone advice or visits from the original
hospital team.
Data about the long-term outcome of opioid switching
performed in hospital are virtually non-existent, and data
on switching performed at home did not provided such
information. In a pharmacoepidemiological study from a
national Norwegian prescription database of 168 cancer
patients who were switched to methadone, 22% of patients
received prescriptions of other opioids and more than 75%
received subsequent dispensed prescriptions of methadone.
This suggests that a large proportion of cancer patients
experience a lasting benefit from switching to methadone.
The study also reported that many treatment options had
not been exhausted prior to the switch to methadone4.
One retrospective study provided information on a long-
term period after opioid switching and was performed in an
outpatient setting. Switching to methadone was consid-
ered effective in about 85% of patients at either the first
follow-up visit (on average 13 days after switching) and the
Table 2. Mean pain intensity and distress score (DS) in patients with assessments at T0, T2 and T4. No. of patients with a NRS of 0–5
versus 6–10.
T0 T2 T4 p-value
Pain intensity (mean SD) 2.6 (1.6) 3.7 (1.9) 3.6 (2.4) 0.007 T2 vs. T0*
0.025 T4 vs. T0*
DS (mean SD) 5.2 (2.5) 7.4 (4.8) 7.4 (3.4) 0.007 T2 vs. T0*
0.002 T4 vs. T0*
No. of patients with pain 0–5/6–10 32/0 28/4 25/7 0.022y
*Paired Wilcoxon signed-rank test.
yPearson’s chi-square test.
Table 1. Number of patients who maintained the same opioid and the same
doses or required changes in therapy between T0 and T2, T2 and T4, and
between T0 and T4.
T0–T2 T2–T4 T0–T4
Maintaining the same dose 16 19 13
Increasing the dose 5 7 8
Decreasing the dose 8 1 4
Switch to another opioid 3 4 7
Adding another opioid 1 1*
*One patient had a dose increment and another opioid was added at T4(n.4).
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second follow-up visit (on average 28 days after switching).
One month after switching, 84% of patients continued
receiving methadone. Doses of methadone were low, rang-
ing from 18 to 20mg/day5. Moreover, this group of ambu-
latory patients was presumably seen at an early stage of
disease, giving the low rate of deaths in the period consid-
ered, which was different from the overall population
examined in this study.
The principal limitations of this study were the short
survival of patients and the assessment performed in a set-
ting where the responsibility of the subsequent treatment
may reside with other people, including GP, hospice, or
home palliative care program, despite continuous phone
contact by a hospital team. Of interest, half of patients
were coming from distant provinces. In some cases avail-
ability of drugs may be limited in these situations. Finally,
relatives may have played a negative role because of cul-
tural attitudes. Thus, the choice of the subsequent treat-
ment depends on several variables. These problems were
expected and are probably insurmountable, reflecting the
reality of what happens in this category of patient. Thus, a
more strict collaboration is advisable to provide the best
care for advanced cancer patients who move from a spe-
cialized setting to another. Nevertheless the treatment was
effectively long-lasting in the majority of patients
In conclusion, opioid switching performed in an acute
pain relief and palliative care is an effective method of
improving the balance between analgesia and adverse
effects, even for prolonged periods of time, after being
discharged to another setting of care. However, for a
variety of different reasons, some of them may lose this
benefit. More studies using different models of care
should be performed to gather further information about
the long-term outcome of opioid switching.
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